ClinicalTrials.gg
CompletedNCT04052425Updated Aug 22, 2025Results posted

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

A Phase 3 interventional study of Ruxolitinib cream and Vehicle in Non-segmental Vitiligo, sponsored by Incyte Corporation. Completed at 57 sites in 8 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.

Enrollment
3rd of 14
330 · median 90
Started
2019
with 1 other
Phase 3
6 of 14
3 open now
Registered
3rd of 14
by date
Lead sponsor
9 of 14
Incyte Corporation

Among the 14 studies testing ruxolitinib in Vitiligo, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 6 in phase 3, and was the 3rd registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ruxolitinib in Vitiligo, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).

03

Conditions studied

  • Non-segmental Vitiligo

Browse trials for

Keywords

  • Vitiligo
  • non-segmental
  • JAK inhibitor
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Clinical diagnosis of non-segmental vitiligo with depigmented area including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, ≥ 3 T-VASI, and total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.
  • Agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.
  • Must be willing to take appropriate measures to avoid pregnancy or fathering a child for the duration of study participation.

Key Exclusion Criteria:

  • No pigmented hair within any of the vitiligo areas on the face.
  • Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor).
  • Have used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas.
  • Use of protocol-defined treatments within the indicated before baseline.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    Double-Blind Period: Ruxolitinib cream 1.5% BID

    Participants applied ruxolitinib 1.5% cream twice daily (BID) for 24 weeks.

    Drug: Ruxolitinib cream

  • Placebo comparator
    Double-Blind Period: Vehicle cream BID

    Participants applied matching vehicle cream BID for 24 weeks.

    Drug: Vehicle

  • Experimental
    Treatment-Extension Period: Ruxolitinib cream 1.5% BID

    Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied ruxolitinib cream 1.5% BID during the Double-Blind Period continued to apply ruxolitinib cream 1.5% BID for an additional 28 weeks in the Treatment-Extension Period.

    Drug: Ruxolitinib cream

  • Experimental
    Treatment-Extension Period: Vehicle cream to Ruxolitinib cream 1.5% BID

    Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied vehicle cream BID during the Double-Blind Period applied ruxolitinib cream 1.5%m BID for 28 weeks in the Treatment-Extension Period.

    Drug: Ruxolitinib cream · Drug: Vehicle

Interventions

  • Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

    Also known as: INCB018424 cream

  • DrugVehicle

    Vehicle cream is a topical formulation applied as a thin film to affected areas.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24

    An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

Secondary outcomes

  1. Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Week 24

    An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

  2. Percentage of Participants Achieving a ≥ 90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Week 24

    An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

  3. Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Week 24

    A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

  4. Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) of 4 or 5 at Week 24

    The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.

    Time frame: Baseline; Week 24

  5. Percentage Change From Baseline in Facial Body Surface Area (F-BSA) at Week 24

    F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 24

  6. Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

    Time frame: from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to Week 24)

  7. Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

    Time frame: from the completion of the Week 24 assessments until at least 30 days after the last application of study drug (up to Week 52 + 30 days)

  8. Percentage of Participants Achieving a ≥ 25% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25) Score at Week 24

    An F-VASI25 responder achieved at least 25% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

  9. Percentage of Participants Achieving a ≥ %25, ≥ %50, ≥ 75%, and ≥ 90% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25/50/75/90) Score at Week 52

    An F-VASI25/50/75/90 responder achieved at least 25/50/75/90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; Week 52

  10. Percentage Change From Baseline in F-VASI at Week 24

    F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 24

  11. Percentage Change From Baseline in F-VASI at Week 52

    F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 52

  12. Percentage Change From Baseline in F-BSA at Week 52

    F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 52

  13. Percentage Change From Baseline in T-VASI at Week 24

    T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 24

  14. Percentage Change From Baseline in T-VASI at Week 52

    T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 52

  15. Percentage Change From Baseline in T-BSA at Week 24

    T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 24

  16. Percentage Change From Baseline in T-BSA at Week 52

    T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 52

  17. Percentage of Participants Achieving a ≥ 25%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/75/90) Score at Week 24

    A T-VASI25/75/90 responder achieved at least 25/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

  18. Percentage of Participants Achieving a ≥ 25%, ≥ 50%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/50/75/90) Score at Week 52

    A T-VASI25/50/75/90 responder achieved ≥25/50/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: Baseline; Week 52

  19. Percentage of Participants in Each Category of VNS During the Treatment Period (Double-Blind and Treatment-Extension Periods)

    The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.

    Time frame: Baseline; Week 24 and Week 52

  20. Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24

    The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "Prevented work or studying" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

    Time frame: Baseline; Week 24

  21. Change From Baseline in DLQI at Week 52

    The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "Prevented work or studying" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

    Time frame: Baseline; Week 52

  22. Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) During the Treatment Period (Double-Blind and Treatment-Extension Periods)

    The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. The CDLQI is the youth/children's version of the DLQI and was completed by adolescents aged ≥ 12 years to \< 16 years. Each question is scored as: very much = 3; quite a lot = 2; only a little = 1; not at all = 0; question unanswered = 0. For Question 7: "Prevented school" = 3. The CDLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

    Time frame: Baseline; Week 24 and Week 52

  23. Trough Plasma Concentrations of Ruxolitinib at Weeks 4, 24, and 40

    Trough plasma concentration was defined as the measurement of the plasma concentration of ruxolitinib before drug application.

    Time frame: pre-dose at Weeks 4, 24, and 40

07

Results

Posted Sep 21, 2022

Participant flow

This study was conducted at 45 study centers in North America and Europe.

24-Week Double-blind Period
Participant flow — 24-Week Double-blind Period
MilestoneDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Started22110900
Completed1939000
Not completed281900
Withdrew: Adverse event0100
Withdrew: Lack of efficacy0100
Withdrew: Lost to follow-up14700
Withdrew: Physician decision1000
Withdrew: Protocol violation1000
Withdrew: Withdrawal by subject91000
Withdrew: Discontinued treatment due to covid-19 pandemic3000
28-Week Treatment-Extension Period
Participant flow — 28-Week Treatment-Extension Period
MilestoneDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Started0019390
Completed0017480
Not completed001910
Withdrew: Adverse event0010
Withdrew: Lack of efficacy0010
Withdrew: Lost to follow-up0051
Withdrew: Physician decision0001
Withdrew: Withdrawal by subject00107
Withdrew: Sponsor opinion due to safety reason0010
Withdrew: Participant moved0011

Outcome measures

PrimaryPercentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24

An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 2429.87.4
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = < 0.0001 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 5.28 · 95% CI 2.341 to 11.903
SecondaryPercentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Week 24

An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Week 2451.216.9
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = < 0.0001 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 5.18 · 95% CI 2.831 to 9.482
SecondaryPercentage of Participants Achieving a ≥ 90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Week 24

An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage of Participants Achieving a ≥ 90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Week 2415.32.2
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = 0.0038 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 8.49 · 95% CI 1.997 to 36.048
SecondaryPercentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Week 24

A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Week 2420.65.1
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = 0.0020 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 4.93 · 95% CI 1.795 to 13.566
SecondaryPercentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) of 4 or 5 at Week 24

The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) of 4 or 5 at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) of 4 or 5 at Week 2424.53.3
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = 0.0002 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 9.53 · 95% CI 2.900 to 31.290
SecondaryPercentage Change From Baseline in Facial Body Surface Area (F-BSA) at Week 24

F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline in Facial Body Surface Area (F-BSA) at Week 24
percentage changeDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage Change From Baseline in Facial Body Surface Area (F-BSA) at Week 24-28.9 ± 2.22-9.5 ± 3.25
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · ANCOVA · p = < 0.0001 (Response Variable = Treatment + Stratification Factors (Skin Type Fitzpatrick scale Type I, II versus Type III, IV, V, and VI, Region North America/Europe) + Baseline) · Least squares mean difference: -19.3 · 95% CI -27.05 to -11.64
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

Time frame:
from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to Week 24)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period
ParticipantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period10142
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

Time frame:
from the completion of the Week 24 assessments until at least 30 days after the last application of study drug (up to Week 52 + 30 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period
ParticipantsTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period6531
SecondaryPercentage of Participants Achieving a ≥ 25% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25) Score at Week 24

An F-VASI25 responder achieved at least 25% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 25% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25) Score at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage of Participants Achieving a ≥ 25% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25) Score at Week 2469.830.0
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = < 0.0001 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 5.56 · 95% CI 3.226 to 9.578
SecondaryPercentage of Participants Achieving a ≥ %25, ≥ %50, ≥ 75%, and ≥ 90% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25/50/75/90) Score at Week 52

An F-VASI25/50/75/90 responder achieved at least 25/50/75/90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ %25, ≥ %50, ≥ 75%, and ≥ 90% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25/50/75/90) Score at Week 52
percentage of participantsTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
F-VASI2589.674.4
F-VASI5075.156.1
F-VASI7552.626.8
F-VASI9032.912.2
SecondaryPercentage Change From Baseline in F-VASI at Week 24

F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline in F-VASI at Week 24
percentage changeDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage Change From Baseline in F-VASI at Week 24-47.79 ± 2.43-17.18 ± 3.53
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · mixed-effect model; repeated measurement · p = <0.0001 · Least squares mean difference: -30.61 · 95% CI -39.03 to -22.19
SecondaryPercentage Change From Baseline in F-VASI at Week 52

F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 52
Reported as:
Mean · percentage change
Percentage Change From Baseline in F-VASI at Week 52
percentage changeTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Percentage Change From Baseline in F-VASI at Week 52-67.24 ± 33.660-52.98 ± 30.174
SecondaryPercentage Change From Baseline in F-BSA at Week 52

F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 52
Reported as:
Mean · percentage change
Percentage Change From Baseline in F-BSA at Week 52
percentage changeTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Percentage Change From Baseline in F-BSA at Week 52-44.87 ± 43.954-32.40 ± 30.068
SecondaryPercentage Change From Baseline in T-VASI at Week 24

T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline in T-VASI at Week 24
percentage changeDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage Change From Baseline in T-VASI at Week 24-27.60 ± 1.81-10.62 ± 2.64
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · mixed-effect model; repeated measurement · p = <0.0001 · Least squares mean difference: -16.98 · 95% CI -23.28 to -10.68
SecondaryPercentage Change From Baseline in T-VASI at Week 52

T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 52
Reported as:
Mean · percentage change
Percentage Change From Baseline in T-VASI at Week 52
percentage changeTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Percentage Change From Baseline in T-VASI at Week 52-49.23 ± 26.366-29.85 ± 37.832
SecondaryPercentage Change From Baseline in T-BSA at Week 24

T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline in T-BSA at Week 24
percentage changeDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage Change From Baseline in T-BSA at Week 24-13.08 ± 1.40-4.02 ± 2.05
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · mixed-effect model; repeated measurement · p = 0.0003 · Least squares mean difference: -9.07 · 95% CI -13.96 to -4.18
SecondaryPercentage Change From Baseline in T-BSA at Week 52

T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 52
Reported as:
Mean · percentage change
Percentage Change From Baseline in T-BSA at Week 52
percentage changeTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Percentage Change From Baseline in T-BSA at Week 52-27.39 ± 25.705-11.83 ± 34.654
SecondaryPercentage of Participants Achieving a ≥ 25%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/75/90) Score at Week 24

A T-VASI25/75/90 responder achieved at least 25/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 25%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/75/90) Score at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
T-VASI2548.823.8
T-VASI754.11.8
T-VASI900.50.0
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = < 0.0001 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 3.04 · 95% CI 1.746 to 5.307
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = 0.2921 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 2.30 · 95% CI 0.489 to 10.823
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · Odds ratio (or): 0.49
SecondaryPercentage of Participants Achieving a ≥ 25%, ≥ 50%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/50/75/90) Score at Week 52

A T-VASI25/50/75/90 responder achieved ≥25/50/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
Baseline; Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 25%, ≥ 50%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/50/75/90) Score at Week 52
percentage of participantsTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
T-VASI2577.556.1
T-VASI5053.231.7
T-VASI7520.29.8
T-VASI903.52.4
SecondaryPercentage of Participants in Each Category of VNS During the Treatment Period (Double-Blind and Treatment-Extension Periods)

The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.

Time frame:
Baseline; Week 24 and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants in Each Category of VNS During the Treatment Period (Double-Blind and Treatment-Extension Periods)
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Week 24, more noticeable6.214.4——
Week 24, as noticeable17.446.7——
Week 24, slightly less noticeable51.335.6——
Week 24, a lot less noticeable24.13.3——
Week 24, no longer noticeable1.00.0——
Week 52, more noticeable——4.04.9
Week 52, as noticeable——9.215.9
Week 52, slightly less noticeable——46.859.8
Week 52, a lot less noticeable——39.319.5
Week 52, no longer noticeable——0.60.0
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) at Week 24

The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "Prevented work or studying" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24
scores on a scaleDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24-1.17 ± 0.27-0.85 ± 0.39
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · mixed-effect model; repeated measurement · p = 0.4970 · Least squares mean difference: -0.32 · 95% CI -1.26 to 0.62
SecondaryChange From Baseline in DLQI at Week 52

The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "Prevented work or studying" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

Time frame:
Baseline; Week 52
Reported as:
Mean · scores on a scale
Change From Baseline in DLQI at Week 52
scores on a scaleTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Baseline4.63 ± 4.4464.59 ± 4.871
Week 52-1.40 ± 4.087-1.37 ± 3.617
SecondaryChange From Baseline in Children's Dermatology Life Quality Index (CDLQI) During the Treatment Period (Double-Blind and Treatment-Extension Periods)

The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. The CDLQI is the youth/children's version of the DLQI and was completed by adolescents aged ≥ 12 years to \< 16 years. Each question is scored as: very much = 3; quite a lot = 2; only a little = 1; not at all = 0; question unanswered = 0. For Question 7: "Prevented school" = 3. The CDLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

Time frame:
Baseline; Week 24 and Week 52
Reported as:
Mean · scores on a scale
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) During the Treatment Period (Double-Blind and Treatment-Extension Periods)
scores on a scaleDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Baseline2.50 ± 2.8051.25 ± 1.893——
Week 24-0.25 ± 2.1130.00 ± 0.000——
Week 52——-1.00 ± 2.5070.00 ± 1.000
SecondaryTrough Plasma Concentrations of Ruxolitinib at Weeks 4, 24, and 40

Trough plasma concentration was defined as the measurement of the plasma concentration of ruxolitinib before drug application.

Time frame:
pre-dose at Weeks 4, 24, and 40
Reported as:
Mean · nanomoles
Trough Plasma Concentrations of Ruxolitinib at Weeks 4, 24, and 40
nanomolesDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Week 457.1 ± 61.4———
Week 2456.3 ± 69.4———
Week 40——55.5 ± 63.650.1 ± 55.8

Adverse events

Collected over from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to Week 52 + 30 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Cream BID0/109 (0%)1/109 (0.9%)0/109 (0%)
Ruxolitinib Cream 1.5% BID0/311 (0%)8/311 (2.6%)0/311 (0%)
Most frequent serious events
Most frequent serious events
EventVehicle Cream BIDRuxolitinib Cream 1.5% BID
Tibia fractureInjury, poisoning and procedural complications1/1090/311
Anal fistulaGastrointestinal disorders0/1091/311
AppendicitisInfections and infestations0/1091/311
ConcussionInjury, poisoning and procedural complications0/1091/311
Hepatitis infectious mononucleosisInfections and infestations0/1091/311
HypersensitivityImmune system disorders0/1091/311
Kidney contusionInjury, poisoning and procedural complications0/1091/311
MyocarditisCardiac disorders0/1091/311
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1091/311
Subacute combined cord degenerationNervous system disorders0/1091/311

Baseline characteristics

Baseline data are reported for members of the Safety Population, comprised of all participants who applied ruxolitinib cream or vehicle cream at least once. Treatment groups for this population were determined according to the actual treatment the participant applied on Day 1.

Age, Continuous
Age, Continuous(years)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Mean40.5 ± 15.4439.7 ± 16.7140.2 ± 15.85
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Female13650186
Male8559144
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
White — White18096276
White — Black/African American11415
White — Asian549
White — American Indian/Alaska Native101
White — Not Reported16319
White — Latino314
White — Hispanic or Latino101
White — Iranian101
White — Indian112
White — Hispanic101
White — Black-Hispanic101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Hispanic or Latino532073
Not Hispanic or Latino15186237
Not Reported15318
Unknown101
Captured as "Other"101
Face Vitiligo Area Scoring Index (F-VASI)
Face Vitiligo Area Scoring Index (F-VASI)(scores on a scale)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Mean0.932 ± 0.58130.999 ± 0.59420.954 ± 0.5855
Facial Body Surface Area (F-BSA) Involvement
Facial Body Surface Area (F-BSA) Involvement(percentage of facial surface area)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Mean1.05 ± 0.6921.15 ± 0.7101.09 ± 0.698
Total Body Vitiligo Area Scoring Index (T-VASI)
Total Body Vitiligo Area Scoring Index (T-VASI)(scores on a scale)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Mean6.489 ± 2.02286.424 ± 1.92416.467 ± 1.9881
Total Body Surface Area (T-BSA) Involvement
Total Body Surface Area (T-BSA) Involvement(percentage of total body surface area)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Mean7.28 ± 2.0337.22 ± 2.0087.26 ± 2.022
08

Study locations

57 sites
  • Cahaba Dermatology
    Hoover, Alabama 35244, United States
  • Cognitive Clinical Trials Scottsdale Btc Ppds
    Scottsdale, Arizona 85260, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • First Oc Dermatology
    Fountain Valley, California 92708, United States
  • Marvel Clinical Research Llc
    Huntington Beach, California 92647, United States
  • Rady Children'S Hospital - San Diego
    San Diego, California 92123, United States
  • University of California San Francisco Sub Location
    San Francisco, California 94158, United States
  • Clinical Research Center of Ct
    Danbury, Connecticut 06810, United States
  • Harmony Medical Research Institute
    Hialeah, Florida 33016, United States
  • San Marcus Research Clinic Inc.
    Miami Lakes, Florida 33014, United States
  • ForCare Medical Center
    Tampa, Florida 33613, United States
  • Forcare Clinical Research Fcr Forward Clinical Trials, Inc
    Tampa, Florida 33624, United States
  • Metabolic Research Institute Inc
    West Palm Beach, Florida 33401, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Clinical Trials Management Llc
    Metairie, Louisiana 70006, United States
  • Great Lakes Research Group Inc
    Bay City, Michigan 48706, United States
  • Dermatology Specialists of Brighton
    Brighton, Michigan 48114, United States
  • Suny Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Forest Hills Dermatology Group
    Forest Hills, New York 11375, United States
  • The Dermatology Specialists Greenwich
    New York, New York 10012, United States
  • Wake Research Associates Llc
    Raleigh, North Carolina 27612, United States
  • Wake Forest University
    Winston-Salem, North Carolina 27157, United States
  • Kgl Skin Study Center
    Broomall, Pennsylvania 19008, United States
  • Dermatology Associates of Plymouth Meeting
    Plymouth Meeting, Pennsylvania 19462, United States
  • Palmetto Clinical Trial Services
    Anderson, South Carolina 29621, United States
  • International Clinical Research Tennessee Llc
    Murfreesboro, Tennessee 37130, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Dermatology Specialists of Spokane
    Spokane, Washington 99202, United States
  • Multiprofile Hospital For Active Treatement - Clinic of Dermatology and Venerology
    Pleven, 05800, Bulgaria
  • DCC 28
    Sofia, 01592, Bulgaria
  • Medical Center Eurohealth
    Sofia, 01606, Bulgaria
  • Dermatology Research Institute
    Calgary, Alberta T1Y 0B4, Canada
  • Institute For Skin Advancement
    Calgary, Alberta T3A 2N1, Canada
  • Skin Centre For Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • Windsor Clinical Research Inc
    Windsor, Ontario N8W 5L7, Canada
  • McGill University Health Centre / Carey/Wang Clinic
    Montreal, Quebec H3Z2S6, Canada
  • Siena Medical Reserch Corporation
    Westmount, Quebec H3Z 2S6, Canada
  • Centre Hospitalier Universitaire de Nantes
    Nantes, 44000, France
  • Chu de Nice - Hopital L'Archet 1
    Nice, 06202, France
  • Hopital Charles Nicolle Chu Rouen - Hopital de Bois-Guillaume
    Rouen, 76031, France
  • Chu de Toulouse Hopital Larrey Centre de Reference Des Maladies Rares de La Peau Service de Dermatol
    Toulouse, 31059, France
  • University Clinic Carl Gustav Carus, Technical University Dresden
    Dresden, 01307, Germany
  • Universitatsklinik Munster Dermatologie
    Münster, 48149, Germany
  • Presidio Ospedaliero Piero Palagi
    Florence, 50125, Italy
  • Istituto Dermatologico San Gallicano
    Rome, 00144, Italy
  • Synexus - Polska Sp Z Oo Oddzial W Gdansk
    Gdansk, 80-382, Poland
  • Synexus Polska Sp. Z O.O. Oddzial W Gdyni
    Gdynia, 81-537, Poland
  • Synexus - Sp Z Oo Oddzial W Katowice
    Katowice, 40-040, Poland
  • Dermedic Dr. Zdybski
    Ostrowiec, 27-400, Poland
  • Synexus Polska Sp. Z O.O. Oddzial W Poznaniu
    Poznan, 60-702, Poland
  • Poradnia Dermatologiczno-Wenerologiczna Mediderm S.C. Nzoz
    Torun, 87-100, Poland
  • Synexus Polska Sp. Z O.O. Oddzial We Wroclawiu
    Wroclaw, 50-381, Poland
  • Hospital Cima Sanitas
    Barcelona, 08034, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario San Cecilio
    Granada, 18016, Spain
  • Clinica Universidad de Navarra (Cun)
    Pamplona, 31008, Spain
09

References and documents

Publications

  • Rosmarin D, Pandya AG, Passeron T, Forman SB, Zdybski J, Amster M, Feser C, Papp KA, Nuara A, Kornacki D, Wei S, Ren H, Harris JE, Ezzedine K. Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo. Dermatol Ther (Heidelb). 2025 Dec;15(12):3703-3716. doi: 10.1007/s13555-025-01555-3. Epub 2025 Oct 22. PubMed 41125994 ↗
  • Seneschal J, Wolkerstorfer A, Desai SR, Grimes P, Ezzedine K, Pandya AG, Kornacki D, Wei S, Passeron T, Rosmarin D. Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies. Dermatol Ther (Heidelb). 2025 May;15(5):1227-1238. doi: 10.1007/s13555-025-01381-7. Epub 2025 Mar 29. PubMed 40156697 ↗
  • Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K; TRuE-V Study Group. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022 Oct 20;387(16):1445-1455. doi: 10.1056/NEJMoa2118828. PubMed 36260792 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Mar 2021, 17 months.

Results were first posted in Sep 2022, 1 year 6 months after primary completion. A results delay was requested in Mar 2022.

Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2019
First posted
Aug 9, 2019
StartActual
Sep 20, 2019
Primary completionActual
Mar 18, 2021
CompletionActual
Oct 21, 2021
Results delay requested
Mar 8, 2022
Results first posted
Sep 21, 2022
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04052425
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Aug 9, 2019
Start date
Sep 20, 2019
Primary completion
Mar 18, 2021
Completion
Oct 21, 2021
Results posted
Sep 21, 2022
Last update
Aug 22, 2025

Study contacts

Kathleen Butler, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion